Skip to main content
GutCited

Lactobacillus rhamnosus GG per Antibiotic-Associated Diarrhea (AAD)

A

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

In sintesi

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Effetto: L. rhamnosus GG used by 91.8% None

Popolazione: Italian primary care pediatricians

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Effetto: None None

Popolazione: Pediatric patients with GI disorders

Controlled Clinical Trial n=24 2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days vs: LPS-only group (no probiotics) Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines) Effetto: None p<0.05 to <0.001

Popolazione: Male Wistar albino rats with LPS-induced sepsis

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: Pediatric population

Randomized Controlled Trial Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain) vs: Placebo Outcome: Antibiotic-associated diarrhea incidence Effetto: None None

Popolazione: Adult patients receiving antibiotics

Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745 vs: Placebo or standard care Outcome: AAD prevention and pediatric gastroenteritis Effetto: None None

Popolazione: AAD and gastroenteritis patients (review)

Key Statistics

20

Studi

4000

Partecipanti

Positive

A

Grado

Referenced Papers

Journal of pediatric … 2016 233 citazioni
Digestive diseases (Basel, … 2016 37 citazioni
Journal of clinical … 2015 35 citazioni
Current opinion in … 2009 82 citazioni
Advances in biochemical … 2008 535 citazioni
The Journal of … 2007 265 citazioni
The American journal … 2001 648 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

Limite massimo: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Mixed 279
None -- Positive --
10^9 CFU/day for 14 days 2 weeks Positive 24
None -- Mixed --
Probiotics (multi-strain) -- Positive --
S. boulardii CNCM I-745 -- Positive --
None -- Positive --
Twice daily -- Neutral 2650

Momento migliore per l'assunzione: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • Rare reports of bacteremia in severely immunocompromised individuals
  • Occasional loose stools during adjustment period
  • Very rare: systemic infection in critically ill patients with central venous catheters

Interazioni note

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • Antifungals (no known interaction but may affect gut flora balance)

Livello di assunzione massimo tollerabile: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Antibiotic-Associated Diarrhea (AAD)

Lactobacillus rhamnosus GG per altre condizioni

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.